[{"id":"f62d8147-2a38-4f77-b038-bf10198180d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06561620","created_at":"2025-02-27T08:10:23.102Z","updated_at":"2025-02-27T08:10:23.102Z","phase":"Phase 4","brief_title":"Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients","source_id_and_acronym":"NCT06561620","lead_sponsor":"Fudan University","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Semena (befotertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 592","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-08-22"},{"id":"16896edc-3832-476d-9d58-e04e0d7e8704","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015568","created_at":"2023-08-29T16:10:10.492Z","updated_at":"2024-07-02T16:35:38.745Z","phase":"Phase 1","brief_title":"Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation","source_id_and_acronym":"NCT06015568","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Semena (befotertinib) • pamvatamig (MCLA-129)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 11/04/2028","primary_completion_date":" 11/04/2028","study_txt":" Completion: 07/04/2029","study_completion_date":" 07/04/2029","last_update_posted":"2023-08-29"}]